



Bernhard Nocht Institute for Tropical Medicine
P.O. Box 50 06 40, 22706 Hamburg, Germany

Dr Henning Gädeke, the Chair of the Global Health
EDCTP3 Joint Undertaking Governing Board
c/o Dr Michael Makanga, the Global Health EDCTP3
Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

Prof. Dr. Jürgen May
Chair of the Board
Head Dept. Infectious Disease Epidemiology

Bernhard-Nocht-Str. 74
20359 Hamburg, Germany
phone +49 40 285380-261

02 September 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of Bernhard Nocht Institute for Tropical Medicine (BNITM), Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The BNITM, a foundation under public law, is dedicated to research, training and service with the aim to efficiently control tropical diseases and, in due pursuance of this mission, seeks firm and sustainable collaborations with health authorities, academic institutions and teaching hospitals in areas where tropical diseases are prevalent, and one of the prime aims of BNITM is to contribute to the training of clinical scientists in clinical research and clinical trials according to Good Clinical Practice (GCP).

In the absence of feedback from Global Health EDCTP3 before the proposal deadline, this document serves as a provisional letter of endorsement:

BNITM commits to contribute in-kind (IKOP) support. This support includes personnel costs and travel costs. This contribution strengthens the ability of the JU to deliver on its objectives by ensuring seamless project coordination, high-quality clinical trial implementation and monitoring, and diligent data management for the FACT project.

BNITM contribution falls in four project areas of the FACT project: Project coordination (lead), Clinical trials (responsibility for IMP supply and clinical monitoring), Data management and statistical analysis (lead) and Health economics and social sciences (lead). It covers provision of

additional manpower for the FACT project, travel costs for conference attendance and consortium meeting attendance of additional team members and working appliances.

We estimate the total value of this contribution to be EUR 1,467,300 for the 60-month duration of the project as in-kind contribution:

- Personnel costs: EUR 1,332,300 (additional time for study coordinator, 2 senior researchers, additional staff for data management, clinical monitoring and leadership responsibilities)
- Travel costs: EUR 135,000 (travel to scientific conferences and consortium meetings for additional personnel)

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes, and particularly the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done based on the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,


Prof. Dr. Jüngen May
Chair of the Board

02 September 2025